News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cubist Pharmaceuticals, Inc. (CBST) Could Be An Acquisition Target For Needy Pfizer Inc. (PFE)



8/18/2014 9:51:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The timing may be right for a takeover of Cubist Pharmaceuticals Inc. (CBST)

The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist. The $4.8 billion drug developer is preparing to introduce four new medicines by 2020 to combat bacterial infections that have become resistant to older therapies because of decades of overuse.

Help employers find you! Check out all the jobs and post your resume

Read at Bloomberg
Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES